Bioinformatic Analysis for the Validation of Novel Biomarkers for Cancer Diagnosis and Drug Sensitivity

Background: The genetic control of tumour progression presents the opportunity for bioinformatics and gene expression data to be used as a basis for tumour grading. The development of a genetic signature based on microarray data allows for the development of personalised chemotherapeutic regimes. Method: ONCOMINE was utilised to create a genetic signature for ovarian serous adenocarcinoma and to compare the expression of genes between normal ovarian and cancerous cells. Ingenuity Pathways Analysis was also utilised to develop molecular pathways and observe interactions with exogenous molecules. Results: The gene signature demonstrated 98.6% predictive capability for the differentiation between borderline ovarian serous neoplasm and ovarian serous adenocarcinoma. The data demonstrated that many genes were related to angiogenesis. Thymidylate synthase, GLUT-3 and HSP90AA1 were related to tanespimycin sensitivity (p=0.005). Conclusions: Genetic profiling with the gene signature demonstrated potential for clinical use. The use of tanespimycin alongside overexpression of thymidylate synthase, GLUT-3 and HSP90AA1 is a novel consideration for ovarian cancer treatment.

[1]  Ronald W. Davis,et al.  Quantitative Monitoring of Gene Expression Patterns with a Complementary DNA Microarray , 1995, Science.

[2]  B. Schweitzer,et al.  Dihydrofolate reductase as a therapeutic target , 1990, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[3]  Y. Zhang,et al.  Critical role of arachidonic acid-activated mTOR signaling in breast carcinogenesis and angiogenesis , 2013, Oncogene.

[4]  F. Zunino,et al.  Overview of tumor cell chemoresistance mechanisms. , 2005, Methods in molecular medicine.

[5]  A. Harris,et al.  Targeting the hypoxia-inducible factor (HIF) pathway in cancer , 2009, Expert Reviews in Molecular Medicine.

[6]  S. Kaye,et al.  New antimetabolites in cancer chemotherapy and their clinical impact. , 1998, British Journal of Cancer.

[7]  Yudong D. He,et al.  Gene expression profiling predicts clinical outcome of breast cancer , 2002, Nature.

[8]  A. Olshen,et al.  Inhibition of heat shock protein 90 function down-regulates Akt kinase and sensitizes tumors to Taxol. , 2003, Cancer research.

[9]  R. Strausberg,et al.  Oncogenomics and the development of new cancer therapies , 2004, Nature.

[10]  Ie-Ming Shih,et al.  The Origin and Pathogenesis of Epithelial Ovarian Cancer: A Proposed Unifying Theory , 2010, The American journal of surgical pathology.

[11]  M. Charbonneau,et al.  Transforming Growth Factor β1 Induces Hypoxia-inducible Factor-1 Stabilization through Selective Inhibition of PHD2 Expression* , 2006, Journal of Biological Chemistry.

[12]  M. Baum,et al.  Alternative mechanisms of action of anti-oestrogens , 2004, Breast Cancer Research and Treatment.

[13]  Leslie Wilson,et al.  βIII-Tubulin Induces Paclitaxel Resistance in Association with Reduced Effects on Microtubule Dynamic Instability* , 2005, Journal of Biological Chemistry.

[14]  Jae K. Lee,et al.  A strategy for predicting the chemosensitivity of human cancers and its application to drug discovery , 2007, Proceedings of the National Academy of Sciences.

[15]  Gangduo Wang,et al.  Vascular endothelial growth factor modulates cisplatin sensitivity in human ovarian carcinoma , 2003 .

[16]  Shiaw-Yih Lin,et al.  Dual functions of the homeoprotein DLX4 in modulating responsiveness of tumor cells to topoisomerase II-targeting drugs. , 2013, Cancer research.

[17]  L. Gianni,et al.  Anthracyclines: Molecular Advances and Pharmacologic Developments in Antitumor Activity and Cardiotoxicity , 2004, Pharmacological Reviews.

[18]  Z. Siddik.  Mechanisms of Action of Cancer Chemotherapeutic Agents: DNA-Interactive Alkylating Agents and Antitumour Platinum-Based Drugs , 2005 .

[19]  D. Martincic,et al.  Topoisomerase II inhibitors. , 2005, Cancer chemotherapy and biological response modifiers.

[20]  P. Johnston,et al.  Molecular mechanisms of drug resistance , 2005, The Journal of pathology.

[21]  E. Rowinsky.  The development and clinical utility of the taxane class of antimicrotubule chemotherapy agents. , 1997, Annual review of medicine.

[22]  B. Blagg,et al.  Novobiocin and additional inhibitors of the Hsp90 C-terminal nucleotide-binding pocket. , 2008, Current medicinal chemistry.

[23]  Young Tae Kim,et al.  NM23 as a prognostic biomarker in ovarian serous carcinoma , 2008, Modern Pathology.

[24]  M. Ratain,et al.  Topoisomerase I Inhibitors. , 1997, The oncologist.

[25]  D. Dhar,et al.  Expression of metastin and a G-protein-coupled receptor (AXOR12) in epithelial ovarian cancer. , 2007, European journal of cancer.

[26]  K. Strimbu,et al.  What are biomarkers? , 2010, Current opinion in HIV and AIDS.

[27]  J. Grem,et al.  Thymidylate synthase inhibitors. , 2001, Cancer chemotherapy and biological response modifiers.

[28]  W. W. Solinge,et al.  Management of gene promoter mutations in molecular diagnostics. , 2009 .

[29]  J. Isaacs,et al.  Hsp90 as a Gatekeeper of Tumor Angiogenesis: Clinical Promise and Potential Pitfalls , 2010, Journal of oncology.

[30]  T. D'arcy,et al.  Potential predictors of chemotherapy response in ovarian cancer--how do we define chemosensitivity? , 2007, Gynecologic oncology.

[31]  Rebecca Lynn Johnson,et al.  Topoisomerase IIα Expression in Breast Cancer: Correlation with Outcome Variables , 2000, Modern Pathology.

[32]  T. Wilson,et al.  Chemoresistance in solid tumours. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[33]  D. Huntsman,et al.  Caspase-1α Is Down-regulated in Human Ovarian Cancer Cells and the Overexpression of Caspase-1α Induces Apoptosis , 2005 .

[34]  L. Dubeau,et al.  The cell of origin of ovarian epithelial tumours. , 2008, The Lancet. Oncology.

[35]  M. Shah,et al.  Cell cycle-mediated drug resistance: an emerging concept in cancer therapy. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[36]  G. Heinze,et al.  Vascular Endothelial Growth Factor Gene Polymorphisms Are Associated with Prognosis in Ovarian Cancer , 2007, Clinical Cancer Research.

[37]  D. Banerjee,et al.  Thymidylate synthase as an oncogene? , 2004, Cancer cell.

[38]  C. Cordon-Cardo,et al.  Expression of ras proto-oncogene proteins in normal human tissues. , 1987, Oncogene.

[39]  R. Dodge,et al.  The prognostic significance of angiogenesis in epithelial ovarian carcinoma. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[40]  D. Huntsman,et al.  Caspase-1alpha is down-regulated in human ovarian cancer cells and the overexpression of caspase-1alpha induces apoptosis. , 2005, Cancer research.

[41]  Guidance on the use of paclitaxel in the treatment of ovarian cancer , 2003 .

[42]  Q. Teng,et al.  Combined Delivery of Paclitaxel and Tanespimycin via Micellar Nanocarriers: Pharmacokinetics, Efficacy and Metabolomic Analysis , 2013, PloS one.

[43]  H. Herweijer,et al.  Multidrug resistance (mdr) genes in human cancer. , 1991, British Journal of Cancer.

[44]  J. Flanagan,et al.  Heterodimers of Placenta Growth Factor/Vascular Endothelial Growth Factor , 1996, The Journal of Biological Chemistry.

[45]  M. Geller,et al.  Angiogenesis in normal and neoplastic ovaries , 2005, Angiogenesis.

[46]  Liotta La.  An attractive force in metastasis. , 2001 .

[47]  Anil K Sood,et al.  Early events in the pathogenesis of epithelial ovarian cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[48]  C. Rinker-Schaeffer,et al.  Thinking outside the box: using metastasis suppressors as molecular tools. , 2011, Seminars in cancer biology.

[49]  C. Gomez-Fernandez,et al.  Expression of GLUT-1 glucose transporter in borderline and malignant epithelial tumors of the ovary. , 2000, Gynecologic oncology.

[50]  R. Chari.  Targeted cancer therapy: conferring specificity to cytotoxic drugs. , 2008, Accounts of chemical research.

[51]  Scott W. Lowe,et al.  Apoptosis A Link between Cancer Genetics and Chemotherapy , 2002, Cell.

[52]  E. Espinosa,et al.  Classification of anticancer drugs--a new system based on therapeutic targets. , 2003, Cancer treatment reviews.

[53]  김덕환,et al.  위암에서 Thymidylate Synthase의 발현에 대한 연구 , 2000 .

[54]  H. Hollema,et al.  DNA topoisomerase IIα and -β expression in human ovarian cancer , 1999, British Journal of Cancer.

[55]  C. Klein,et al.  The Metastasis Cascade , 2008, Science.

[56]  F. Kaye,et al.  Thymidylate synthase as an oncogene: a novel role for an essential DNA synthesis enzyme. , 2004, Cancer cell.

[57]  S. Palmer,et al.  Trastuzumab for the Treatment of HER2-Positive Metastatic Gastric Cancer , 2013, PharmacoEconomics.

[58]  S. Adelstein,et al.  Integrative Genomic Data Mining for Discovery of Potential Blood-Borne Biomarkers for Early Diagnosis of Cancer , 2008, PloS one.

[59]  W. Linehan.  The genetic basis of kidney cancer , 2014 .

[60]  B. Baguley.  Multiple Drug Resistance Mechanisms in Cancer , 2010, Molecular biotechnology.

[61]  Syed Mohsin,et al.  Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer , 2003, The Lancet.

[62]  V. Castranova,et al.  A population-based gene signature is predictive of breast cancer survival and chemoresponse. , 2010, International journal of oncology.

[63]  M. Tomasz,et al.  Mechanism of monofunctional and bifunctional alkylation of DNA by mitomycin C. , 1988, Biochemistry.

[64]  R. Spang,et al.  Predicting the clinical status of human breast cancer by using gene expression profiles , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[65]  J. Mason,et al.  Folate and carcinogenesis: an integrated scheme. , 2000, The Journal of nutrition.

[66]  P. Neven,et al.  Tamoxifen, screening and new oestrogen receptor modulators. , 2001, Best practice & research. Clinical obstetrics & gynaecology.

[67]  S. Antonia,et al.  Indoleamine 2,3-Dioxygenase: Is It an Immune Suppressor? , 2010, Cancer journal.

[68]  Inna N Lavrik,et al.  Caspases: pharmacological manipulation of cell death. , 2005, The Journal of clinical investigation.

[69]  S. Rashid,et al.  Hallmarks of Cancer Cell , 2017 .

[70]  L. V. van Putten,et al.  Proliferation-dependent cytotoxicity of anticancer agents: a review. , 1975, Cancer research.

[71]  M. Shibuya,et al.  Tumor cell-derived placental growth factor sensitizes antiangiogenic and antitumor effects of anti-VEGF drugs , 2012, Proceedings of the National Academy of Sciences.

[72]  J. Lotem,et al.  NQO1 stabilizes p53 through a distinct pathway , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[73]  E. Dahl,et al.  Altered expression pattern of topoisomerase IIalpha in ovarian tumor epithelial and stromal cells after platinum-based chemotherapy. , 2006, Neoplasia.

[74]  G M Tozer,et al.  Hypoxia modulated gene expression: angiogenesis, metastasis and therapeutic exploitation. , 2000, European journal of cancer.

[75]  M. Fukumoto,et al.  Thymidylate Synthase Expression in Epithelial Ovarian Cancer: Relationship with Thymidine Phosphorylase Expression and Prognosis , 2000, Oncology.

[76]  T. Ozben.  Mechanisms and strategies to overcome multiple drug resistance in cancer , 2006, FEBS letters.

[77]  A. Giaccia,et al.  Opposing effects of hypoxia on expression of the angiogenic inhibitor thrombospondin 1 and the angiogenic inducer vascular endothelial growth factor. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[78]  M. Los,et al.  Caspases and cancer: mechanisms of inactivation and new treatment modalities. , 2004, Experimental oncology.

[79]  Margie D. Lee,et al.  Early Events in the Pathogenesis of Avian Salmonellosis , 1999, Infection and Immunity.

[80]  T. Barrette,et al.  ONCOMINE: a cancer microarray database and integrated data-mining platform. , 2004, Neoplasia.

[81]  M. Federico,et al.  Ovarian Cancer: Can Proteomics Give New Insights for Therapy and Diagnosis? , 2013, International journal of molecular sciences.

[82]  Paul Workman,et al.  Gene and protein expression profiling of human ovarian cancer cells treated with the heat shock protein 90 inhibitor 17-allylamino-17-demethoxygeldanamycin. , 2007, Cancer research.

[83]  S. Negrotto,et al.  [Angiogenesis in cancer]. , 2002, Medicina.

[84]  K. Kohno,et al.  [Multidrug resistance (MDR)]. , 1994, Gan to kagaku ryoho. Cancer & chemotherapy.

[85]  A. Chow.  Cell Cycle Control by Oncogenes and Tumor Suppressors: Driving the Transformation of Normal Cells into Cancerous Cells , 2010 .

[86]  F. Ismail-Beigi,et al.  Dual Control of glut1 Glucose Transporter Gene Expression by Hypoxia and by Inhibition of Oxidative Phosphorylation* , 1997, The Journal of Biological Chemistry.

[87]  M. Biondi,et al.  MMP1 and MMP3 polymorphisms in promoter regions and cancer. , 2000, Clinical chemistry.

[88]  Q. Felty,et al.  Oncomine meta-analysis of breast cancer microarray data identifies upregulation of NRF-1 expression in human breast carcinoma , 2009 .

[89]  D. R. Lewis,et al.  Cancer survival and incidence from the Surveillance, Epidemiology, and End Results (SEER) program. , 2003, The oncologist.

[90]  J. Barrett,et al.  Loss of expression and altered localization of KAI1 and CD9 protein are associated with epithelial ovarian cancer progression. , 2002, Gynecologic oncology.

[91]  A. Levine,et al.  The p53 tumour suppressor gene , 1991, Nature.

[92]  K K Jain,et al.  Personalised medicine for cancer: from drug development into clinical practice , 2005, Expert opinion on pharmacotherapy.

[93]  S. Nicosia,et al.  Vascular endothelial growth factor levels in ovarian cyst fluid correlate with malignancy. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[94]  L. Neckers,et al.  Modulation of p53, ErbB1, ErbB2, and Raf-1 expression in lung cancer cells by depsipeptide FR901228. , 2002, Journal of the National Cancer Institute.

[95]  G. Semenza,et al.  Structural and functional analysis of hypoxia-inducible factor 1. , 1997, Kidney international.

[96]  B. Kirschbaum,et al.  Comparative gene-expression analysis. , 1999, Trends in biotechnology.

[97]  D. Kerr,et al.  Predictive biomarkers: a paradigm shift towards personalized cancer medicine , 2011, Nature Reviews Clinical Oncology.

[98]  J. Snyder,et al.  Microtubule-interacting drugs for cancer treatment. , 2003, Trends in pharmacological sciences.

[99]  R. Reisfeld,et al.  Doxorubicin conjugated with a monoclonal antibody directed to a human melanoma-associated proteoglycan suppresses the growth of established tumor xenografts in nude mice. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[100]  N. Miller,et al.  Molecular profiling techniques and bioinformatics in cancer research. , 2007, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[101]  H. M. Sobell.  Actinomycin and DNA transcription. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[102]  M. Gottesman.  Mechanisms of cancer drug resistance. , 2002, Annual review of medicine.

[103]  Till Acker,et al.  Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions , 2001, Nature Medicine.

[104]  M. Smith,et al.  Predictive biomarkers for personalised anti-cancer drug use: discovery to clinical implementation. , 2010, European journal of cancer.

[105]  G. Colditz,et al.  A functional polymorphism in the promoter of the progesterone receptor gene associated with endometrial cancer risk , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[106]  C. Sawyers,et al.  Targeted cancer therapy , 2004, Nature.

[107]  H. Katagiri,et al.  Mechanisms of Ovarian Cancer Metastasis: Biochemical Pathways , 2012, International journal of molecular sciences.